{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-026119","form_type":"8-K","ticker":"ENSC","cik":"0001716947","company_name":"Ensysce Biosciences, Inc.","filed_at":"2022-09-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.768470+00:00","generated_at":"2026-06-23T09:08:37.131021+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Ensysce Biosciences CMO Dr. Nily Osman resigns; Dr. William Schmidt appointed interim CMO","bullets":["Dr. Nily Osman resigned as Chief Medical Officer effective September 15, 2022.","Dr. William K. Schmidt appointed interim Chief Medical Officer effective same date; he previously served as CMO from Jan 2016 to Apr 2022.","Dr. Schmidt has over 25 years of pharma experience and led clinical development for Entereg (alvimopan) at Adolor Corporation."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-026119","json":"https://secwatch.observer/filing/0001493152-22-026119.json","markdown":"https://secwatch.observer/filing/0001493152-22-026119.md","text":"https://secwatch.observer/filing/0001493152-22-026119.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716947/000149315222026119/0001493152-22-026119-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716947/000149315222026119/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T09:08:37.131021+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7dec2c9168","claim":"Dr. William K. Schmidt was appointed as interim Chief Medical Officer at Ensysce Biosciences, Inc..","evidence_excerpt":"The Company has appointed Dr. William K. Schmidt, Ph.D. as the Company's interim Chief Medical Officer, effective as of September 15, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1716947/000149315222026119/0001493152-22-026119-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"interim Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"9c12d2a1a3","claim":"Dr. Nily Osman resigned as Chief Medical Officer at Ensysce Biosciences, Inc..","evidence_excerpt":"tender of resignation from its Chief Medical Officer, Dr. Nily Osman, such resignation effective as of September 15, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1716947/000149315222026119/0001493152-22-026119-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}